155 related articles for article (PubMed ID: 20229596)
1. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
[TBL] [Abstract][Full Text] [Related]
3. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
[TBL] [Abstract][Full Text] [Related]
4. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
Nishi H; Mathäs R; Fürst R; Winter G
J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
[TBL] [Abstract][Full Text] [Related]
5. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
[TBL] [Abstract][Full Text] [Related]
6. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.
Abdul-Fattah AM; Truong-Le V; Yee L; Nguyen L; Kalonia DS; Cicerone MT; Pikal MJ
J Pharm Sci; 2007 Aug; 96(8):1983-2008. PubMed ID: 17286290
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
Schüle S; Friess W; Bechtold-Peters K; Garidel P
Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
[TBL] [Abstract][Full Text] [Related]
8. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation.
Kiese S; Pappenberger A; Friess W; Mahler HC
J Pharm Sci; 2010 Feb; 99(2):632-44. PubMed ID: 19548315
[TBL] [Abstract][Full Text] [Related]
9. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
Nayak A; Colandene J; Bradford V; Perkins M
J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of syringe surfaces on protein formulations.
Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
[TBL] [Abstract][Full Text] [Related]
11. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
Werk T; Volkin DB; Mahler HC
Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
[TBL] [Abstract][Full Text] [Related]
12. A critical evaluation of self-interaction chromatography as a predictive tool for the assessment of protein-protein interactions in protein formulation development: a case study of a therapeutic monoclonal antibody.
Le Brun V; Friess W; Bassarab S; Mühlau S; Garidel P
Eur J Pharm Biopharm; 2010 May; 75(1):16-25. PubMed ID: 20102739
[TBL] [Abstract][Full Text] [Related]
13. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.
Breen ED; Curley JG; Overcashier DE; Hsu CC; Shire SJ
Pharm Res; 2001 Sep; 18(9):1345-53. PubMed ID: 11683251
[TBL] [Abstract][Full Text] [Related]
14. Mechanically-induced aggregation of the monoclonal antibody cetuximab.
Lahlou A; Blanchet B; Carvalho M; Paul M; Astier A
Ann Pharm Fr; 2009 Sep; 67(5):340-52. PubMed ID: 19695370
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.
Gandhi S; Ren D; Xiao G; Bondarenko P; Sloey C; Ricci MS; Krishnan S
Pharm Res; 2012 Jan; 29(1):209-24. PubMed ID: 21845507
[TBL] [Abstract][Full Text] [Related]
16. Particle size coarsening induced by valve silicone in a metered dose inhaler.
Sherwood JK; Alex S; Salama G; Obenauer-Kutner L; Huyck S; Berry J; Sequeira J; Brouet G; Marie C
Drug Dev Ind Pharm; 2007 Feb; 33(2):155-62. PubMed ID: 17454047
[TBL] [Abstract][Full Text] [Related]
17. Shaken, not stirred: mechanical stress testing of an IgG1 antibody.
Kiese S; Papppenberger A; Friess W; Mahler HC
J Pharm Sci; 2008 Oct; 97(10):4347-66. PubMed ID: 18240293
[TBL] [Abstract][Full Text] [Related]
18. Induction and analysis of aggregates in a liquid IgG1-antibody formulation.
Mahler HC; Müller R; Friess W; Delille A; Matheus S
Eur J Pharm Biopharm; 2005 Apr; 59(3):407-17. PubMed ID: 15760721
[TBL] [Abstract][Full Text] [Related]
19. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
Sharma DK; Oma P; Pollo MJ; Sukumar M
J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?
Chang L; Shepherd D; Sun J; Ouellette D; Grant KL; Tang XC; Pikal MJ
J Pharm Sci; 2005 Jul; 94(7):1427-44. PubMed ID: 15920775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
